MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • MDS Virtual Congress 2020

    The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease

    B.G Koçer, E.A Özturk, SS. Çomoğlu (Ankara, Turkey)

    Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…
  • MDS Virtual Congress 2020

    Levodopa Dose Equivalency for Opicapone and Safinamide

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, E. Natera Villalba, A. Beltran Corbellini, A. García Plata, A. Alonso Cánovas (Madrid, Spain)

    Objective: To provide a levodopa dose equivalency (LED) for opicapone and safinamide. Background: Tomlinson at al., provided a schedule to calculate LED of the different…
  • MDS Virtual Congress 2020

    A pilot study on the efficacy, tolerability and safety of safinamide in elderly Parkinson’s disease patients

    D. Rinaldi, M. Sforza, E. Bianchini, S. Galli, F.E Pontieri (Rome, Italy)

    Objective: The aim of the study is to evaluate the efficacy, safety and tolerability of SF (50 and 100 mg / day) in elderly patients…
  • 2019 International Congress

    SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE

    A. Vinagre-Aragón, E. Mondragón-Rezola, I. Croitoru, A. Bergareche-Yarza, JJ. Poza-Aldea, A. Olaskoaga-Caballer, M. Iridoy-Zulet, M. Ruibal-Salgado, JC. Gómez-Esteban, K. Berganzo-Corrales, B. Tijero-Merino, J. Ruiz-Martínez (San Sebastián, Spain)

    Objective: to analyze the long term efficacy and tolerability of safinamide added as adjunctive therapy in a series of patients with Parkinson´s disease (PD) Background:…
  • 2019 International Congress

    Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease

    S. Neo, A. Wong, HL. Ng, W. Li, KY. Tay, WL. Au, L. Tan (Singapore, Singapore)

    Objective: To compare Parkinson’s disease (PD) treatment practices by movement disorder (MD) specialists across a decade, and to determine the factors that influence drug choice…
  • 2019 International Congress

    Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats

    CA. Pisanò, A. Brugnoli, S. Novello, C. Caccia, C. Keywood, E. Melloni, G. Padoani, S. Vailati, M. Morari (Ferrara, Italy)

    Objective: To investigate the effects of safinamide (saf) and rasagiline on in vivo glutamate (Glu) release in the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of Parkinson’s…
  • 2019 International Congress

    Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)

    A. Gómez López, I. Pareés Moreno, S. Fanjul Arbós, JL. López Sendon, JC. Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)

    Objective: We compared the effects of safinamide on the urinary symptoms of Parkinson's disease with other therapies. Background: Urinary symptoms (US) are common, disabling and…
  • 2019 International Congress

    Is safinamide helpful in multiple system atrophy?

    R. Simões, A. Gonçalves, JJ. Ferreira (Lisboa, Portugal)

    Objective: To retrospectively review the clinical benefit of safinamide in patients with Multiple System Atrophy. Background: Safinamide is a new monoamine oxidase-B inhibitor, with dopaminergic…
  • 2019 International Congress

    Can Safinamide Help to Stabilize Dopaminergic Treatment in Parkinson’s Disease?

    B. Solano Vila, A. Cots Foraster, M. Montserrat Roses (Girona, Spain)

    Objective: After more than two years of clinical experience with safinamide  we want to retrospectively review its utility as a levodopa saver in our Parkinson's…
  • 2019 International Congress

    High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients

    C. Carrarini, M. Russo, F. Barbone, F. Dono, M. Rispoli, M. Onofrj, A. Thomas (Chieti, Italy)

    Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley